Funding for Faculty

Siteman Funding Opportunities Newsletter

Download the latest Siteman Funding Opportunities Newsletter (PDF) The newsletter and the list of open opportunities on this page are not fully inclusive of all available cancer-related funding. Please be sure to consult other sources to learn of other opportunities not listed here.

How are we doing? Send us your suggestions! Please let us know how we can improve this page, the newsletter, or anything else related to funding opportunity dissemination. 

Rolling Deadlines: Internal Grant Resources (≤$25K)

BQSR Grant Support – Siteman Biostatistics and Qualitative Research Shared Resource

Additional Details

RFP Snapshot: The Siteman Cancer Center (SCC) Biostatistics and Qualitative Research Shared Resource (BQSR) fulfills a critical function by providing methodologic and analytic support for the development and conduct of scientifically sound, innovative cancer research at SCC. Advances in biotechnologies and computing systems/software increasingly require specialized expertise and tools for sophisticated statistical methodologies. Qualitative research requires sound methods and approaches that support rigor and best practice. The overarching goal of the BQSR is to provide a comprehensive, centralized, and accessible biostatistics and qualitative support infrastructure for all phases of cancer research; from study development and design to data collection, ongoing monitoring, and final analysis.

Max Amount and Period: N/A

Eligibility: Must be a Siteman Cancer Center member.

Due Date: Rolling

WUSTL CDD Match Grants - WUSTL Center for Drug Discovery

Additional Details

RFP Snapshot: The WUSTL Center for Drug Discovery offer the CDD Match Grant15 and Grant25 programs.

Match Grant15 is to advance translational small-molecule drug discovery research at Washington University. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in vivopharmacokinetics for proof-of-concept in vivo pharmacology studies, intellectual property (patent) filing, and drug development.

Match Grant25 is a follow-on award program meant only for those investigators who have successfully completed and met the objectives of a Match Grant15 (or the original CDD MicroGrant) award and request additional match funds to further advance the discovery research project. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in vivo pharmacokinetics for proof-of-concept in vivo pharmacology studies, intellectual property (patent) filing, and drug development.

Max Amount and Period:

Match Grant15 – $7,500 from CDD

Match Grant25 – $12,000 from CDD

Eligibility:

Match Grant15 – open to investigators with a faculty appointment at Washington University

Match Grant25 – open only to WashU faculty who have successfully completed a Match Grant15 (or CDD MicroGrant) and submitted a final research report.

Due Date: Rolling

WUSM ICTS Innovation Awards - Institute of Clinical and Translational Sciences

Additional Details

RFP Snapshot: The purpose of the awards is to advance initial discovery pilots for Precision Health ICTS investigators. Proposals are not for developed projects but are to fund developmental or early stage work, including pilot data collection and analysis, in preparation for submission of future external funding.

Max Amount and Period: $25,000 for 1 year

Eligibility: Applicants must be full time faculty (instructor level or above) at Washington University in St. Louis or an ICTS partner institution. Applicant must be a member of the ICTS.

Due Date: Rolling

WUSM ICTS Just-in-Time (JIT) Core Usage Funding Program - Institute of Clinical and Translational Sciences and Siteman Cancer Center

Additional Details

RFP Snapshot: The Just-In-Time (JIT) Core Usage Funding Program is designed to provide quick access to funding to use any of the JIT Cores (pdf) for research advancing medical knowledge that can improve human health. Siteman Cancer Center will co-sponsor cancer-focused proposals.

Max Amount and Period: Varies

Eligibility: Applicant must be a registered member of the ICTS and hold a faculty level appointment at WUSTL or an ICTS partner institution.

Due Date: Rolling

Rolling Deadlines: External Grant Resources

Project Cure CRC: Preclinical and Clinical Translational Research - Colorectal Cancer Alliance

Additional Details

RFP Snapshot: There is a special emphasis on projects that accelerate existing preclinical and clinical research that increases therapeutic options, improves adjuvant therapies, delivers novel therapies focused on driver mutations (BRAF, TP53, KRAS, BRCA1, as examples) and investigate strategies to influence the tumor microenvironment (TME) to expand the use of immunotherapy. See RFA for other eligible research objective priorities.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applications will be accepted from non-profit, for-profit, and academic organizations, and from investigators who hold MD, PhD, or other professional degrees.

Due Date: Rolling

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Evidence for Action (E4A): Innovative Research to Advance Racial Equity - Robert Wood Johnson Foundation

Additional Details

RFP Snapshot: This funding is geared toward studies about “upstream” causes of health inequities, such as the systems, structures, laws, policies, norms, and practices that determine the distribution of resources and opportunities, which in turn influence individuals’ options and behaviors. Research should center on the needs and experiences of communities exhibiting the greatest health burdens and be motivated by real-world priorities. It should be able to inform a specific course of action and/or establish beneficial practices, not stop at characterizing or documenting the extent of a problem.

Max Amount and Period: No limit for 3 years, but budget must be reasonably supported by scope of project.

Eligibility: Applicant organizations must be based in the US or its territories. Preference will be given to applicant organizations that are either institutes of higher education, public entities, or nonprofits that are tax exempt under Section 501(c)(3) of the Internal Revenue Code.

Due Date: Rolling

Pioneering Ideas: Exploring the Future to Build a Culture of Health - Robert Wood Johnson Foundation

Additional Details

RFP Snapshot: Pioneering Ideas: Exploring the Future to Build a Culture of Health welcomes proposals that are primed to influence health equity in the future. We seek ideas that address any of RWJF’s Pioneering Ideas for an Equitable Future team’s four current areas of focus described below: 1) Future of Evidence; 2) Future of Social Interaction; 3) Future of Food; and 4) Future of Work. Additionally, under Open Exploration, also described below, this call for proposals seeks ideas that might fall outside of these four focus areas but which offer unique approaches to advancing health equity and our progress toward a Culture of Health.

Max Amount and Period: No limit for 3 years, but budget must be reasonably supported by scope of project.

Eligibility: Applicant organizations must be based in the US or its territories. Preference will be given to applicant organizations that are either institutes of higher education, public entities, or nonprofits that are tax exempt under Section 501(c)(3) of the Internal Revenue Code.

Due Date: Rolling

June Deadlines

June 13: 2024 'A' Award Grant - Alex's Lemonade Stand Foundation

Additional Details

RFP Snapshot: The purpose of this program is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to scientists focused on pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. A mentor is required, and a career development
plan must be included.

Max Amount and Period: $800,000 over 4 years

Eligibility: Applicants must have an MD, PhD or MD/PhD (DO, MBBS or equivalent) and be within ten years of their terminal degree and five years of their first faculty appointment as an Assistant Professor at the time that their application is submitted. More senior Assistant Professors, as well as Associate and Full Professors, are ineligible. If still at the Instructor level, the applicant must have a firm commitment from the Department Chair/Division Chief at the time of grant submission for an Assistant Professor position within one year of receiving the award. A minimum of 75% of the applicant’s time must be allocated as non-clinical protected time for all research activities. A mentor must be identified from the applicant’s home institution. Applicants may not be the PI of a K99/R00 or other nationally-competitive award such as an R01 or equivalent, P, or U award. Applicants cannot have 2 R21s or 2 R03s at any time before the award.

Due Date: June 13, 2024 at 7PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 14: Prevent Cancer Foundation Research Grants in Cancer Prevention and Early-Detection

Additional Details

RFP Snapshot: The goal of the Prevent Cancer Foundation’s research program is to identify and to provide seed funding for innovative projects with the potential to make substantial contributions to cancer prevention or early detection. By funding the most promising research, including fellowship projects led by early career scientists, we contribute to important advances in cancer prevention and early detection. Research projects will be aimed at reducing the frequency of neoplasms including but not limited to brain, bladder, breast, colon and rectum, endometrium, head and neck, kidney, liver, lung, ovary, pancreas, prostate, skin (including melanoma), stomach as well as HPV-related cancers and hematologic malignancies.

Max Amount and Period: $100,000 over 2 years

Eligibility: The goal of the Foundation’s research program is to provide seed funding for innovative projects expected to lead to future funding from other peer-reviewed sources. All application must demonstrate substantial near-term potential for impact on cancer prevention or early detection. Pre-clinical research with clear applicability to cancer prevention/early detection is acceptable, provided a translational relationship is evident within 5 years.

Due Date: June 14, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 15: LOI: Ovarian Cancer Pilot Grant Award - Powell Drescher Ovarian Cancer Research Foundation

Additional Details

RFP Snapshot: This grant is meant to encourage preliminary research projects in all areas of ovarian cancer research including, but not limited to, cancer biology, genetics, early detection and prevention, treatment, cancer care delivery, and public health sciences. New concepts, novel approaches, and/or projects that extend previous discoveries and have potential to develop into larger projects are encouraged. To be considered responsive, the research team must include an ovarian cancer advocate, defined in the RFA as an ovarian cancer patient, survivor, family member, caregiver, previvor, or other person touched by ovarian cancer.

Max Amount and Period: $75,000 over 2 years

Eligibility: Applicants must hold the equivalent position of Assistant Professor or higher, have an MD, PhD, ScD, MSW, and/or MSN degree, and have completed their graduate training. Applicants should have a minimum of 50% protected research time.

Due Date: Letter of Intent Due: June 15, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 15: LOI: NBTS Quality of Life Research Project - National Brain Tumor Society

Additional Details

RFP Snapshot: This award will support innovative patient-centered research designed to address critical problems or barriers to progress in the field of brain tumor QoL. The proposed scope of work must include brain tumor research focused on one of the following topics or a combination of the two:
● Supportive and palliative care
● Patient and family brain tumor-related navigation

NBTS welcomes proposals that focus on research questions relevant to QoL for people with brain tumors and their care partners. Projects should focus on research that will work towards 2 improving patient outcomes and that can provide the foundation for future research projects.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants must hold a clinical doctoral degree (e.g., MD, DO) or doctoral degree (e.g., PhD, MD, DrPH) from an accredited institution. They must hold an independent position at an accredited institution and may be at any career stage.

Due Date: Letter of Intent Due: June 15, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 15: AST Research Network Transition to Independence Grants - American Society of Transplantation Research Network

Additional Details

RFP Snapshot: The purpose of the AST Research Network Transition to Independence Research Grants is to promote the careers of academic investigators whose development of an independent research program is focused on the field of basic science, translational and clinical investigation in solid organ transplantation. The grants are intended to provide support for the investigator’s transition to an R-series or equivalent grant.

Max Amount and Period: $115,000 over 2 years

Eligibility: Applicants must have a doctoral degree (MD, DO, PhD, DVM, PharmD, or equivalent), must have completed post-graduate training, and must have obtained an institutional commitment that is sufficient to conduct research and allow for long-term success. The applicants must be active members of the AST or have submitted a completed membership application by the deadline. Applicants may hold a career development grant (e.g. K grant), but may NOT be the PI on a previous or current NIH grant to perform independent research. Applicants may apply for an AST grant at the same time as applying for an NIH R01, P01, or comparable award. See RFA for more details.

Due Date: June 15, 2024 at 11:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 17: Career Development Award (CDA) - Conquer Cancer, The ASCO Foundation

Additional Details

RFP Snapshot: The Career Development Award (CDA) provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects.

Max Amount and Period: $200,000 over 3 years

Eligibility: Applicants must be an MD, DO, or international equivalent working in any country. They must be in the first to fourth year of a full-time primary faculty appointment in a clinical department. Applicants must have completed productive postdoctoral research and demonstrated the ability to undertake independent investigator-initiated clinical research. Applicants must be an ASCO member or submitted a membership application and be able to commit at least 50% of full-time effort in research. Applicants must a have a mentor from the sponsoring institution. Applicants may not hold other concurrent career development awards from private foundations. See RFA for list.

Due Date: June 17, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 17: Young Investigator Award (YIA) for Diversity and Inclusion in Breast Cancer Research - Conquer Cancer, The ASCO Foundation

Additional Details

RFP Snapshot: This YIA is designed with the primary goal of increasing diversity in the oncology workforce and breast cancer research. The YIA will provide funding to promising investigators who identify as members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research. The purpose of this award is to fund physicians during the transition from a fellowship program to a faculty appointment as they seek to build a career in clinical breast cancer research.

Max Amount and Period: $50,000 for 1 year

Eligibility: Applicants must be a physician currently in the last two years of their final oncology subspecialty training and within 10 years of obtaining their medical degree. Applicants must identify as members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research (according to the AAMC definition – includes but not limited to: American Indian/Alaska Native, Black/African American, Hispanic/Latino, and Native Hawaiian/Other Pacific Islander). Must be able to commit at least 60% of full-time effort to total research. Must be an ASCO member or have submitted a membership with the grant application. Applicants must also have a mentor in the proposed research field.

Due Date: June 17, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 20: LOI: ASH-EHA Translational Research Training in Hematology - American Society of Hematology / European Hematology Association

Additional Details

RFP Snapshot: This training is intended for trainees and junior faculty engaged in laboratory-based translational and basic science research. Trainees and faculty holding MDs, MD/PhDs, biomedical PhDs, or pharmacy PharmDs (or equivalents) are encouraged to apply.

Max Amount and Period: Week-long course held in spring, year-long mentoring

Eligibility: Applicants must be a trainee or junior faculty and hold an MD and/or PhD or biomedical PhD or pharmacy PharmD degree (or equivalents) in basic and translation research in classical or malignant hematology. MD applicants must be within twelve years of post-graduation at the time of the deadline for full application. PhD applicants must have less than eight years of post-doc experience after graduation at the time of the deadline for full application. Applicants holding both an MD and a PhD must be within 12 years of MD-graduation. Exceptions may be made for interruptions in an applicant’s academic pursuits. Applicants must be actively employed in a hematology or hematology-related research environment. Both the applicant and the applicant’s mentor should be either an EHA member, or an ASH member at the time of LOI submission and throughout the term of the award program.

Due Date: June 20, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 24: LOI: AUA Data Research Program - American Urological Association

Additional Details

RFP Snapshot: The AUA instated the AUA Data Research Program (formerly AUA Data Grants) with the aim of connecting the urology research community to vast AUA resources. The AUA Data Research Program will encourage the broad use of AUA data, with the assistance of AUA Statisticians and the AUA Data Committee. The newly approved Data Research Program is also intended to stimulate the use of AUA data sources for knowledge generation and dissemination.

Max Amount and Period:
• Access to Annual Census and AQUA Registry
• Statistical analysis support
• $2,000 stipend for travel, presentation, publication costs

Eligibility: Applicants must be AUA members.

Due Date: Letter of Intent Due: June 23, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 25: Addressing Knowledge Gaps in Aplastic Anemia - Global - Pfizer

Additional Details

RFP Snapshot: This competitive grant program seeks to support educational activities that address knowledge gaps related to aplastic anemia. This mechanism will NOT support clinical research projects. The geographic scope is global (excluding the United States). Projects that will be considered for Pfizer support will focus on improving the care of patients by addressing knowledge gaps in the following areas: 1) early identification and diagnosis of aplastic anemia (AA) patients; 2) awareness of AA, in order to ensure appropriate transition of patients to specialty clinical centers of excellence for care; 3) current standards for the treatment of AA and its complications; 4) clinical management of special patient subpopulations (i.e. Pediatrics or Elderly) and challenging cases of AA patients.

Max Amount and Period: $50,000 over 2 years

Eligibility: The applicant must be the project/program lead or an authorized designee of such individual. If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.

Due Date: June 25, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 26: Improving Care for Patients with Hodgkin and Non-Hodgkin’s Lymphoma - Pfizer

Additional Details

RFP Snapshot: This competitive program seeks to provide educational grants to support continuing education projects focused on the evolving treatment landscape for patients with Hodgkin, T-Cell, and Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL). Applicants are encouraged to identify and address the educational needs, barriers, and gaps for patients with Hodgkin Lymphoma, T-Cell Lymphoma, and R/R DLBCL relating to treatments, management of adverse events, and long-term outcomes. Proposed activities should focus on increasing clinicians’ knowledge, confidence, competence, and practice changes in caring for patients. This may include interactive learning, case-based learning, workshops, tumor boards, digital platforms, building communities of practice, and other live programs.

Max Amount and Period: $200,000 over 12-15 months

Eligibility: The applicant must be the project/program lead or an authorized deisngee of such individual. If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.

Due Date: June 26, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 27: F Cancer Young Investigator Award in Lung Cancer in Memory Barbara Berlanti - Conquer Cancer, The ASCO Foundation

Additional Details

RFP Snapshot: The purpose of this YIA is to fund physicians during the transition from a fellowship program to a faculty appointment. This is a mentored award and research projects are conducted under the guidance of a mentor. Applications are accepted from U.S. and international applicants.

Max Amount and Period: $50,000 for 1 year

Eligibility: Eligible applicants must be physicians (MD, DO, or international equivalent) in the last two years of final oncology subspecialty training and within 10 years of obtaining their medical degree. Applicants must be planning an investigative career in clinical oncology with a focus on lung cancer research specifically on early detection, screening, risk identification and/or prevention. Applicants must have a mentor in the proposed research field from the sponsoring institution and be an active ASCO member. Applicants must also be able to commit at least 60% of full-time effort to research.

Due Date: June 27, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 27: New Mechanisms and Emerging Treatment Options in Metastatic Breast Cancer - Pfizer

Additional Details

RFP Snapshot: This competitive program seeks to support independent medical education activities focused on the evolving treatment landscape for patients with ER+/HER2 mBC. Applicants are encouraged to identify and address the educational needs of healthcare professionals related to novel treatments in the evolving clinical landscape of ER+/HER2- mBC. Proposed educational activities should focus on increasing the understanding of emerging mechanisms of action (MOA) of novel agents – particularly in the post-CDK4/6 inhibitor(s) setting.

Max Amount and Period: $175,000 over 15 months

Budget above is maximum. Smaller, focused projects with lower budgets are preferred.

Eligibility: The applicant must be the project/program lead or an authorized deisngee of such individual. If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.

Due Date: June 27, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 28: MMRF Research Fellow Award - Multiple Myeloma Research Foundation

Additional Details

RFP Snapshot: The Research Fellowship Program is an initiative supporting early career researchers at the post-doctorate, medical fellow, or junior faculty levels currently active or interested in research in multiple myeloma. The goal of this initiative is to engage and support early career investigators interested in basic and clinical research focused on multiple myeloma and its precursor conditions, with the goal of advancing our understanding of myeloma disease biology, disease risk, and treatment response and relapse.

Max Amount and Period: $150,000 over 2 years

Eligibility: The MMRF Fellowship program is targeted to early career scientists. Applicants must have obtained their highest degree within 10 years of the application date. Post-doctorate and medical fellows applying for the award must work under the supervision of a research mentor in the multiple myeloma field. Applicants may not hold a position higher than Assistant Professor. Applicants who are beginning studies in the multiple myeloma field must have a research sponsor/mentor at their institution who is active in the multiple myeloma field, and who can provide guidance to the applicant in the proposed area of research. MMRF strongly encourages Black, Indigenous, and People of Color (BIPOC) scientists and clinicians interested in multiple myeloma research to apply.

Due Date: June 28, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 30: Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials - NIH/NCI

Additional Details

RFP Snapshot: This NOSI is to encourage current grant or cooperative agreement awardees to apply for administrative supplement funds to support the development of tools and strategies to increase the participation of individuals from all population subgroups who are representative of people for whom the parent grant intervention may be indicated. DCP led or co-led programs appropriate for this opportunity include Cancer Prevention and Control Clinical Trials Grant Program, Cancer Prevention Clinical Trials Network (CP-CTNet), NCI Community Oncology Research Program (NCORP) Research Bases, NCORP Community Sites and NCORP Minority/Underserved Community Sites, Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers Program and the NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub. The proposed strategies and tools should be designed to promote inclusion of historically underserved populations in clinical trials – by identifying and reducing enrollment barriers at the organizational, participant, or protocol design level.

Max Amount and Period: $125,000 for 1 year (cannot exceed the costs of the current parent award)

Eligibility: Eligible Parent Awards: R01, UG1, U01, U24, and U54. Parent award must be active, and cannot be in a no-cost extension.

Due Date: June 30, 2024 at 5PM CST

June 30: LOI: 2024 AAMDSIF Research Grant - Aplastic Anemia and MDS International Foundation

Additional Details

RFP Snapshot: These research grants will support investigators dedicated to studying bone marrow failure and advancing the understanding, prevention and treatment of bone marrow disorders in both pediatric and adult populations. In 2024, the AAMDSIF Research Grant Program will accept proposals in the following categories:
• Aplastic Anemia (focus on acquired)
• Myelodysplastic Syndromes/Neoplasms (MDS)
o MDS transition to Acute Myeloid Leukemia (AML)
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Inherited bone marrow failure syndromes
In addition, proposals addressing the prevention or treatment of graft-vs-host disease (GVHD) related to hematopoietic
stem cell transplantation for bone marrow failure disease will be accepted in the 2024 grant cycle.

Max Amount and Period: $60,000 over 2 years

Eligibility: Eligible applicants will hold a MD, PhD, DO, D.Sc, or PharmD degree. Preference will be given to New Investigators who propose a project that will contribute toward their professional development in bone marrow failure disease research. New Investigators are post-doctoral fellows, Instructors, and those who have been Assistant Professors for fewer than five (5) years.

Due Date: Letter of Intent Due: June 30, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

June 30: Siteman Trainee Travel Awards - Siteman Cancer Center

Additional Details

RFP Snapshot: The Siteman Trainee Travel Award supports scholars in career development related to cancer research or cancer health disparities research by providing reimbursement (i.e. registration, airfare, hotel, etc.) to present research at conferences and/or attend workshops/trainings. Scholars who are Underrepresented in Medicine (URiM) and/or women are strongly encouraged to apply.

Max Amount and Period: $1,500 in travel funds

Eligibility: Trainee must be affiliated with Siteman Cancer Center, Washington University, BJC, Children’s Hospital, SLU, or University of Missouri. All cancer related research and cancer disparities research trainees encouraged to apply. Priority given to NCI affiliated trainees. Must be a pre-doctoral trainee (doctoral student), postdoctoral trainee, research fellow, or early career faculty (instructor or assistant professor who has not yet held an R01 award). Conference location must be within the domestic USA; includes Canada, Mexico, and US Territories. This award may be used as a supplement to other scholarships, but may not be used to duplicate other resources.

Due Date: June 30, 2024 at 10:59PM CST

July Deadlines

July 1: LOI: Childhood Cancer Research Grants - Pablove Foundation Seed Grants

Additional Details

RFP Snapshot: The Pablove Foundation invests in underfunded, cutting-edge pediatric cancer research and improves the lives of children living with cancer through the arts. Our mission is built on our impassioned desire to know more, find better, less toxic treatments, and a cure, and allow kids living with cancer to still be kids while undergoing treatment. Preferences going toward less common childhood cancers.

Max Amount and Period: $50,000 for 1 year

Eligibility: All the Powered by Pablove Seed Grants are designed for researchers currently towards the end of their clinical fellowship or postdoctoral training or within five (5) years of completion of training. Applicants must have an MD or PhD or equivalent degree. International applicants and institutions are welcome to apply for all grants; there is no residency requirement. Past Powered by Pablove grant recipients are not eligible to apply. Multiple LOI submissions for the same principal investigator, even if for different grant opportunities, are not allowed. Multiple applications are permitted from a single institution.

Due Date: Letter of Intent Due: July 1, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

July 1: LOI: Opsoclonus Myoclonus Syndrome (OMS) Grants - Pablove Foundation Seed Grants

Additional Details

RFP Snapshot: The Pablove Foundation invests in underfunded, cutting-edge pediatric cancer research and improves the lives of children living with cancer through the arts. Our mission is built on our impassioned desire to know more, find better, less toxic treatments, and a cure, and allow kids living with cancer to still be kids while undergoing treatment. Preferences going toward less common childhood cancers. This special interest opportunity welcomes broad ranging applications applicable to OMS, including from investigators who are in a clinical fellowship, postdoctoral training, or are
established investigators.

Max Amount and Period: $100,000 over 2 years

Eligibility: All the Powered by Pablove Seed Grants are designed for researchers currently towards the end of their clinical fellowship or postdoctoral training or within five (5) years of completion of training. Applicants must have an MD or PhD or equivalent degree. International applicants and institutions are welcome to apply for all grants; there is no residency requirement. Past Powered by Pablove grant recipients are not eligible to apply. Multiple LOI submissions for the same principal investigator, even if for different grant opportunities, are not allowed. Multiple applications are permitted from a single institution.

Due Date: Letter of Intent Due: July 1, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

July 1: AACR-Novocure Career Development Award for Cancer Research - American Association for Cancer Research

Additional Details

RFP Snapshot: This grant represents a joint effort to promote and support early-career investigators who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field. The Inovitro® system (which will provided by Novocure, if needed), must be included in the experimental design.

Max Amount and Period: $300,000 over 3 years

Eligibility: Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Applicants must hold a faculty position with the title of Instructor, Research Assistant Professor, or Assistant Professor. They must have received their first faculty position with the past six years, i.e. must have begun their appointment on December 1, 2018 or later.

Due Date: July 1, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

July 1: AACR-Novocure Cancer Research Grants - American Association for Cancer Research

Additional Details

RFP Snapshot: This grant represents a joint effort to promote and support independent investigators who are currently conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage independent investigators to enter the TTFields research field. The Inovitro® system (which will be provided by Novocure, if needed), must be included in the experimental design.

Max Amount and Period: $350,000 over 3 years

Eligibility: Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Current AACR Grantees may apply if their current grant ends before the start of the grant term of this funding opportunity i.e., December 1, 2024, and must be up to date with all reporting requirements to be considered eligible. Applicants must also be AACR Active members in good standing.

Due Date: July 1, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

July 8: Damon Runyon-Rachleff Innovation Award, Stage 1 - Damon Runyon Cancer Research Foundation

Additional Details

RFP Snapshot: The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.

Max Amount and Period: $400,000 over 2 years

Eligibility: Applicants (including non-U.S. citizens) must be conducting independent research at a U.S. research institution. The applicant must have received an MD, DO, PhD, or MD/PhD degree(s) from an accredited institution. Basic and translational/clinical projects will be considered. Applications will be accepted from all scientific disciplines provided that the proposed research meets the selection criteria.

Due Date: July 8, 2024 at 3PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

July 9: LOI: Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research - American Association for Cancer Research

Additional Details

RFP Snapshot: This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that may not be funded through conventional channels. It is expected that this grant will catalyze significant scientific discoveries and help talented young investigators gain scientific independence. Fanconi anemia (FA) is a rare genetic disease caused by loss-of-function mutations in any one of 22 FA genes, which are integral to the FA/BRCA DNA repair pathway and include the breast cancer susceptibility genes BRCA1 and BRCA2. The disease is marked by congenital abnormalities, bone marrow failure, and a high risk of solid tumors and leukemia. Individuals with FA have a hundreds- to thousands-fold increased risk of developing squamous cell cancers of the head and neck, esophagus, and anogenital regions, in addition to an elevated risk for other solid tumors.

Max Amount and Period: $450,000 over 3 years

Eligibility: Applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. Applicants must currently hold a tenure-eligible appointment at the rank of Assistant Professor, and they must have begun that appointment on December 1, 2021 or later. Applicants also must be AACR Active members in good standing.

Due Date: Letter of Intent Due: July 9, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

July 15: Hyundai Hope on Wheels Pediatric Cancer Survivorship Collaboration Award

Additional Details

RFP Snapshot: The Survivorship Collaboration Award was developed to provide funding for collaborative research projects focused on pediatric cancer survivorship. The ultimate long-term goal is to improve the quality of life of pediatric cancer survivors. Survivorship Collaboration Awards should be translational in nature, with a clear path to directly impacting patients. Proposals will be judged based on innovation, impact, and clear, measurable and demonstrated outcomes by the end of the three-year period of support.

Max Amount and Period: $1M over 3 years

Eligibility: Eligible applicants for this grant must have a doctoral degree (MD, DO, PhD), a solid track record of involvement in pediatric cancer survivorship, and must be able to commit at least 10% effort to the project. A key component of the Hyundai Survivorship Grant is the requirement for collaboration by two or more institutions, each of which must make must substantial contributions to a shared project.

Due Date: July 15, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

July 23: NCCN Request for Proposals (RFP): Investigator Sponsored Research for Understanding the Mechanisms and Formulating the Optimal Management of Hematological Toxicity of PARPi in the Treatment of Prostate Cancer - NCCN and Pfizer Global Medical Grants

Additional Details

RFP Snapshot: The National Comprehensive Cancer Network® and Pfizer Global Medical Grants (Pfizer) are collaborating to offer a new grant opportunity seeking proposals for investigator-initiated research for the optimal management of hematologic toxicities of PARP inhibitors (PARPi). Pfizer is providing support for research studies proposing to advance the understanding of mechanisms and formulate the optimal management of hematologic toxicity of PARPi in the treatment of patients with prostate cancer.

Max Amount and Period: $250,000 to $500,000 over 2 years
Quality and Pre-Clinical Projects will be capped at $250,000. Clinical Trials will be capped at $500,000

Eligibility: Limited to investigators from NCCN member institutions only. Collaboration between NCCN Member Institutions is strongly encouraged in order to foster the interactive sharing of knowledge and expertise, and to utilize the combined clinical strengths of members, particularly in the case of uncommon tumors. Although the submitting investigator must be from an NCCN Member Institution, participating co-investigators do not need to be at an NCCN Member Institution. This can also include crossinstitutional collaboration. Proposal submssions from junior faculty are encouraged.

Due Date: July 23, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

July 29: LOI: Impacting Blood Cancers Through Clinical Repurposing Trials - Cures Within Reach

Additional Details

RFP Snapshot: This RFP is seeking clinical repurposing trials to address unsolved blood cancers, with a preference for trials impacting multiple myeloma and/or myelodysplastic syndromes. CWR is interested in generic or proprietary approved therapies that could be repurposed to create “new” treatments to 1) reduce the symptoms, progression or incidence of; 2) restore function lost to; or 3) reduce or eliminate severe side effects of currently used therapies for any blood cancer, thereby improving patient outcomes and quality of life.

Max Amount and Period: $75,000 for 1 year

Eligibility: The project must be led either by a previously funded investigator or by an early-stage investigator who has received little or no extramural research funding to date. PIs who have not received extramural funding previously and/or who do not currently have
their own lab should include a Letter of Support from a funded, senior researcher who will act as a mentor for the proposed research and the investigator.

Due Date: Letter of Intent: July 29, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

August Deadlines

August 1: ACS Professor Awards - American Cancer Society

Additional Details

RFP Snapshot: ACS Professor awards are primarily honorific awards for individuals who have made seminal contributions in cancer research. Applicants must be at the rank of full professor and have made, and will likely continue to make, impactful contributions to change the direction of cancer research. These notable cancer research achievements could have been fundamental, preclinical, clinical, psychosocial, behavioral, health policy and/or epidemiologic in focus. Commitment and success in scientific mentoring and leadership as well as community engagement are also carefully considered.

Max Amount and Period: $400,000 over 5 years

Eligibility: Applicants must have obtained the rank of full professor and must be ready to be spokespeople for ACS and for cancer research in general.

Due Date: Letter of Intent Due: August 1, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

August 5: Multi-sectoral Preventive Interventions that Address Social Determinants of Health in Populations that Experience Health Disparities (UG3/UH3, Clinical Trial Required) - NIH/NCI

Additional Details

RFP Snapshot: The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. This opportunity solicits bi-phasic research projects proposed in UG3/UH3 Phased Innovation Awards Cooperative Agreement applications. Funding for the UG3 phase (phase I) will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NIH and prioritized for transition to the UH3 award (phase II). Applicants responding to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases.

Max Amount and Period: $4.75M over 7 years
UG3 Phase – 2 years, UH3 Phase – 5 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

Due Date: August 5, 2024 at 5PM CST

August 15: Damon Runyon-St. Jude Pediatric Cancer Research Fellowship Award

Additional Details

RFP Snapshot: The goal is to fund individuals who propose innovative approaches in either basic or clinical research with the potential to significantly impact the prevention, diagnosis, or treatment of one or more pediatric cancers. Candidates must apply for the Damon Runyon-St. Jude Pediatric Cancer Research Fellowship under the guidance of a Sponsor, a scientist (tenured, tenure-track, or equivalent position) capable of providing mentorship to the Fellow.

Max Amount and Period: $300,000 over 4 years

Eligibility: Applicants must be MD, PhD, MD/PhD, DDS, DVM, Do, or equivalent. Candidates who have already accepted a postdoctoral research fellowship award are not eligible. Candidates may hold a T32 at the time of application, but not concurrently with the Damon Runyon-St. Jude Pediatric Cancer Research Fellowship Award.

• Level 1 Applicants: Basic and physician-scientists must have received their degrees no more than 18 months prior to the application deadline and been in their sponsor’s lab for more than one year prior to the deadline. Applicants are expected to devote 100% of their time to Damon Runyon-supported research.

• Lever 2 Applicants: Physician-scientist applicants (MD, MD/PhD, DDS, DVM, DO or the equivalent) must have completed their residencies and clinical training, must be board eligible in the United States at the start date of the award, and be able to devote at least 80% of their time to Damon Runyon-supported research activities. Applicants may apply at any time prior to their initial assistant professorship appointment (or equivalent); postdoctoral fellows, clinical fellows, and clinical instructors are eligible to apply. Candidates holding or awarded NIH K awards at the time of application are not eligible to apply. Candidates holding institutional K12 awards may apply but must turn-back K12 funding if they are awarded a Damon Runyon-St. Jude Pediatric Cancer Research Fellowship Award.

Due Date: August 15, 2024 at 3PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

August 30: Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional) - NIH/NIMHD/NCI

Additional Details

RFP Snapshot: This NOFO encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.

Max Amount and Period: See RFA for budget details. Max of 10 years.

Eligibility: The program is intended for investigators at the early stages of their independent careers. Applicants will generally have completed or be completing a post-residency clinical fellowship, and will have demonstrated sufficient patient-oriented research experience to qualify for a tenure-track level appointment. Tenured applicants are not eligible. Applicants do not have to be U.S. citizens or permanent residents, although selected Scholars must qualify for and maintain appropriate visa/residency status throughout the program.

Due Date: August 30, 2024 at 5PM CST

August 31: Robert L. Fine Cancer Research Foundation Pancreatic Cancer Research Grants

Additional Details

RFP Snapshot: The grant is intended to support research projects that can be carried out in a short period of time with limited resources. The topic of the requested grant applications will be for innovative translational pancreatic cancer research that focuses on bench to bedside advances. The grant mechanism supports different types of basic and translational projects including pilot and feasibility studies, self-contained research projects, development of new research methodology and development of new research technology. This grant does not support solely clinical research.

Max Amount and Period: $250,000 over 2 years

Eligibility: Must be either Assistant or Associate Professors who have been awarded no more than one R01 or R01 equivalent, including competitive renewals.

Due Date: August 15, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

August 31: Elsa U. Pardee Foundation Grants

Additional Details

RFP Snapshot: This grant is meant to support investigators in the US proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one-year period which will allow the establishment of capabilities of new cancer researchers or new cancer approaches by established cancer researchers. It is anticipated that this early-stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Max Amount and Period: No Limit for 1 year
Budget must be reasonably supported by scope of project.

Eligibility: Priority is given to researchers at non-profit institutions in the United States who are new to the field of cancer research, or to established research investigators examining new approaches to cancer cure. Post-docs who are on the tenure track and have a tenured mentor are eligible.

Due Date: August 31, 2024 at 5PM CST

Application Assistance: Washington University faculty may reach out to Daniel Jaschek in Medical Corporate and Foundation Relations at daniel.jaschek@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

August 31: ACS Extramural Discovery Science Accelerator Award - American Cancer Society

Additional Details

RFP Snapshot: The intent of the Extramural Discovery Science (EDS) Accelerator Award is to support the commercialization of an ongoing cancer research project and to validate and de-risk technologies. Proposals should address key experiment(s) required to move findings toward commercialization that do not easily fit into traditional grant funding mechanisms. This mechanism is not designed to initiate new projects or develop new directions for an ongoing project. The proposal should be commercially driven with the PI having a plan to license the technology, either to an established company or a start-up if the experiment(s) are successful.

Max Amount and Period: $75,000 for 1 year

Eligibility: Applicants must be current or former ACS awardees (including IRG pilot grant awardees), or former ACS postdoctoral fellows. Applicants may be at any career stage, provided they have a full-time faculty appointment. Applicants must be motivated to commercialize their technology.

Due Date: August 31, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

September Deadlines

September 3: Andrew McDonough B+ Foundation Childhood Cancer Research Grant

Additional Details

RFP Snapshot: The B+ Foundation, with the help of a highly respected Scientific Advisory Board, funds cutting-edge childhood cancer research. The B+ Foundation funds grants that support basic, translational or clinical research, which may lead towards cures and better treatments for childhood cancers.

Max Amount and Period: $150,000 over 2 years

Eligibility: Applicants must have a MD, DO, PhD, or PharmD degree. Applicants may be Assistant, Associate, or Full Professors. Additionally, applications will be considered from instructors who have a minimum of a two-year commitment from an accredited academic institution.

Due Date: September 3, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

September 5: Clinical Investigator Career Development Award - Lymphoma Research Foundation

Additional Details

RFP Snapshot: The goal of the program is to prepare physician investigators to design and administer clinical research studies in lymphoma and assume primary responsibilities for clinical research, protocol writing, Institutional Review Board (IRB) submission and publication. As such, a Career Development Plan is required as part of the Grant Application. The proposed research plan should also develop the necessary knowledge and clinical research skills relevant to the investigator’s career goals. The Grant is designed to provide physician investigators with support to spend 35-50 percent of their time implementing clinical research studies in lymphoma.

Max Amount and Period: $225,000 over 3 years

Eligibility: Applicants must be licensed clinical physicians in one of the ACGME accredited specialties (HemOnc, Pediatrics, Pathology, Dermatology, RadOnc) and intending to pursue a career in lymphoma clinical research. Citizenship or permanent residency is not required for general CDA eligibility, but may affect eligibility for Health Equity Initiative funds. The applicant must be an advanced fellow or junior faculty member with at least 2 years (24 months) of fellowship or postdoctoral training and no greater than six years of experience beyond completion of their fellowship or postdoctoral training (the six year limit may be non-sequential) at the start of the award period (March 1, 2025). Applicant must spend 35%-50% of time doing research. Please see RFA for full eligibility requirements.

Due Date: September 5, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

September 5: Lymphoma Scientific Research Mentoring Program (LSRMP) - Lymphoma Research Foundation

Additional Details

RFP Snapshot: The Lymphoma Research Scientific Advisory Board will select up to 6 Scholars in each of the two tracks to become LSRMP Scholars and participate in the Lymphoma Scientific Research Mentoring Program. LSRMP Scholars attend an initial LSRMP workshop which is four days in length. The workshop will take place March 4-7, 2025 in Henderson, Nevada.

Max Amount and Period: $10,000 over 2 years

Eligibility:

Clinical Track: Applicants for this track must be one of the following, with requirements calculated per the applicant’s status as of March 1, 2025: a. a junior faculty member with an MD or equivalent degree in their first five years holding a faculty position. Eligible titles include, but are not limited to, Instructor, Clinical Instructor, Assistant Professor and Clinical Assistant Professor. b. a clinical fellow who is at least in their second year of one of the following ACGME accredited sub-specialty fellowship programs: Hematology/Oncology, Hematology, Medical Oncology, Radiation Oncology, Pediatric Hematology/Oncology, or Hematopathology. Pathology fellows in one-year fellowship programs and applicants from other clinical sub-specialties will be considered based on the application’s description of the relevance of the research and career development plan to lymphoma, please contact [email protected] for eligibility review.

Laboratory/Translational Track: Applicants for this track must be one of the following, with requirements calculated per the applicant’s status as of March 1, 2025: a. A postdoctoral fellow with no more than eight years as a postdoctoral fellow; b. A clinical fellow who is at least in their second year of an appropriate ACGME accredited sub-specialty fellowship programs including: Hematology/Oncology, Hematology, Medical Oncology, Radiation Oncology, Pediatric Hematology/Oncology, or Hematopathology. Pathology fellows in one-year fellowship programs and applicants from other clinical sub-specialties will be considered based on the application’s description of the relevance of the research and career development plan to lymphoma, please contact [email protected] for eligibility review. c. An Instructor (MD, PhD, or equivalent) in their first five years with the title Instructor. MD Instructor applicants should not be more than four years beyond completion of their fellowship or more than twelve years beyond completion of their MD or equivalent degree. PhD Instructor applicants should not be more than thirteen years beyond completion of their PhD or equivalent degree; d. An Assistant Professor (MD, PhD, or equivalent), in the first four years with that title. Assistant Professors must be tenure eligible and spend at least 80% of their time in laboratory research work. They must be the sole PI of their laboratory and must provide an institutional letter documenting commitment to the applicant in terms of space and resources (see item 18, page 16 for details).

Due Date: September 5, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

September 12: LOI: Building Evidence for Effective Interventions to Increase Therapeutic Cancer Clinical Trial Accrual: Promoting Access for Patients from Underrepresented Groups - Leukemia and Lymphoma Society

Additional Details

RFP Snapshot: This funding opportunity is part of LLS’s Equity in Access Research Program, designed to generate evidence that will guide changes in healthcare policy and practice to ensure that all patients with and survivors of a blood cancer have the ability to access and utilize optimal treatment, care, and resources that can improve their quality of life and outcomes, from diagnosis through survivorship. This opportunity seeks to fund proposals that will implement and evaluate interventions designed to a) mitigate barriers to therapeutic clinical trial accrual for underrepresented groups, and b) quantitatively measure the impact of these interventions on patient accrual. LLS will support research that will guide changes in evidence-based practice and policy. LLS is particularly interested in proposals that address systemic, institutional, and/or clinician-related barriers that impede clinical trial participation.

Max Amount and Period: $2.5M over 2 years

Eligibility: LLS welcomes PIs at all stages of their careers as well as PIs who have not previously conducted research in the area of blood cancer. However, if the Principal Investigator is an early investigator, a more experienced Co-Principal Investigator is required. The PI must have a PhD, MD, DO, ScD, JD, or equivalent doctoral degree. Multi-disciplinary teams are strongly encouraged.

Due Date: Letter of Intent Due: September 12, 2024 at 2PM CST

Pre-Application Webinar: Be sure to register for the upcoming pre-app webinar on June 18, 2024 from 11am to noon CST here: https://tlls.zoom.us/webinar/register/WN__kqRZkR0RDKSr2HeBYjmAg#/registration

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.